transsphenoidal resection of functional pituitary adeno mas, 1, [4] [5] [6] [7] 11, 15, 17, 20, 21, 23, 25, 26, 28, 29, 31, 33, 34, 39, 41, [43] [44] [45] [46] there is a paucity of literature reporting the endocrinological outcome fol lowing use of a purely endoscopic transsphenoidal tech nique. 8, 12, 19, 36 Moreover, continuous re-evaluation of en docrinological outcomes following surgical treatment of functional pituitary lesions is necessary to keep up with the latest definitions of postoperative endocrinological remis sion. Based on improvements in followup data, criteria for endocrinological remission following resection have constantly evolved over time. Here we present our singlecenter experience in which we used the latest criteria for an endocrinological cure for PRL-, GH-, and ACTH-secreting adenomas 3, 9, 16 in a cohort treated with a purely endoscopic endonasal transsphenoidal technique.
Methods

Patient Demographic Data
We analyzed a prospectively collected database of all patients who underwent endoscopic endonasal surgery for a functional pituitary adenoma at Weill Cornell Medical College, New York-Presbyterian Hospital between Febru ary 2004 and June 2010, as a collaboration between the de partments of Neurosurgery and Otolaryngology. Function al tumors were resected by the senior authors (T.H.S. and J.A.B.) using a purely endoscopic endonasal transsphenoi dal approach. This study was approved by the institutional review board. For each operation, the duration of surgery, estimated blood loss, relevant laboratory values, adjuvant treatments, and complications were recorded.
Radiographic Evaluation
Prior to resection, all patients underwent contrastenhanced MR imaging. Tumor invasion of the CS was defined according to the following criteria: three-quar ters or more encasement of the internal carotid artery, obliteration of the carotid sulcus venous compartment, or crossing of the lateral intercarotid line by the tumor. 10 Routinely, the surgical site was analyzed by contrast-en hanced MR imaging on postoperative Day 1, 3 months after surgery, and then at yearly intervals.
Surgical Technique
Prior to surgery, all patients received antibiotics and glucocorticoids, and intrathecal fluorescein was used in 73% of cases to label CSF. 32 We use Brainlab neuronavi gation for all of our cases. A detailed description of the procedure has been published previously. 19, 24, 35, 38 Briefly, after application of topical cocaine to the nasal mucosa, the mucosa of the middle turbinates is infiltrated with a mixture of 1% lidocaine and epinephrine (1:100,000). The sphenoid ostia are identified bilaterally and enlarged by removal of bone. We then use a tissue shaver to resect the posterior third of the nasal septum. Using a highspeed drill and curettes, the anterior wall of the sella is opened. We attempt to resect microadenomas en bloc, whereas macroadenomas are first internally decompressed by removing the inferior portion of the tumor, followed by resection of the lateral portions. This maneuver prevents the suprasellar arachnoid from herniating down into the sella. Resection of extensive suprasellar components may require an extended approach to the lesions, including re moval of the tuberculum sellae and planum sphenoidale. 24 Tumor is dissected off the medial CS wall. In case of CS invasion, the dura mater is opened medial to the internal carotid artery, and tumor can be easily removed from this area. Although it is also possible to open the CS lateral to the carotid, one must carefully weigh the safety of this maneuver with the increased extent of resection that it will facilitate, and how this will affect the longterm out come of the patient, compared with treatment with ste reotactic radiosurgery. The skull base defect is closed in a multilayered fashion. 27 
Endocrinological Evaluation
All patients underwent pre and postoperative endo crinological evaluation for free cortisol, ACTH, free thy roxine, thyroid-stimulating hormone, PRL, GH, IGF-I, testosterone, estradiol, luteinizing hormone, and folliclestimulating hormone to assess for endocrinological de rangements (except for 1 patient, who was lost to endocri nological follow-up). The diagnosis of a prolactinoma was made based on serum PRL levels of > 150 ng/ml in com bination with typical clinical symptoms. 9 In patients with prolactinoma, endocrinological remission was defined as postoperative PRL levels of < 20 ng/ml in females or < 15 ng/ml in males. The diagnosis of Cushing disease was based on either abnormal 24-hour urinary free cortisol or abnormal results on low-dose dexamethasone suppres sion tests, defined as failure of 1 mg of dexamethasone to reduce plasma cortisol levels to < 1.8 mg/ml the next morning. 3, 30 In Cushing disease, endocrinological remis sion was defined as an early morning cortisol level mea surement of ≤ 1.8 mg/ml obtained within 48 hours after surgery or a normalization of the 24-hour urinary free cortisol. 3 The diagnosis of acromegaly was based on ab normal basal fasting levels of GH and IGF-I. 16 Biochemi cal remission was defined as a normal IGF-I level com bined with a glucose-suppressed GH level of ≤ 0.4 ng/ml, or alternatively, combined with a basal GH level of ≤ 1 ng/ml. The IGF-I level was always evaluated according to ageadjusted diagrams. 16 
Statistical Evaluation
Continuous variables are shown as the mean values ± the SEM and the range. Categorical values are shown as percentages. Continuous variables between patients with prolactinomas, acromegaly, or Cushing disease were ana lyzed by ANOVA, followed by a Tukey post hoc test. Tu mor diameter between cured and noncured patients was assessed using a Mann-Whitney U-test. Binary logistic regression was used to determine the effect of extent of resection, tumor size, suprasellar extension, and invasion of the CS on endocrinological remission. A conditional backward stepwise method was used to calculate a multi variate logistic regression model. Preoperative and post operative hormone levels in serum were assessed using a paired Student t-test. A p value < 0.05 was considered sig nificant. Statistical analyses were performed using SPSS software (version 18.0 for Macintosh).
Results
Overall Patient Characteristics
At total of 86 patients underwent resection of func tional pituitary adenomas in which a purely endoscopic transsphenoidal technique was used. The cohort was composed of 37 male and 49 female patients with a mean age of 45.2 years (range 12-82 years; Table 1 ). Our series contains 35 patients with prolactinomas, 18 with Cushing disease, and 33 with GH-secreting adenomas. The ma jority of patients (85%) who underwent resection sought medical attention for symptoms related to excess hor mone production. The remaining patients complained of severe headaches (4.7%), diplopia (3.5%), or vision loss (10.5%). Patients with diplopia and vision loss had sig nificantly larger adenomas compared with the rest of the cohort (3.3 cm and 2.6 cm, respectively, vs 1.2 cm maxi mum tumor diameter; p < 0.001). In patients with loss of vision, visual field testing revealed bitemporal defects in 3 patients, binasal defects in 1 patient, or hemianopia in 2 patients. Onethird of patients with acute vision loss where found to have pituitary apoplexy on MR imaging. The remaining 2 patients with apoplexy presented with acute onset of severe headaches. In our cohort, 20.9% of patients had undergone a previous resection. Preoperative MR imaging revealed macroadenomas (maximum diam eter > 1 cm) in two-thirds of our patients. Invasion of the CS was present in 20.9%, and suprasellar tumor extension was detected in 29.1%. Whereas the pituitary-hypotha lamic axis was intact in the majority of patients (89.5%), 6 patients were found to have hypogonadism, 2 had hypo thyroidism, and 1 suffered from both panhypopituitarism and diabetes insipidus prior to surgery.
Surgical Results
Endoscopic endonasal transsphenoidal procedures lasted an average of 167.3 minutes (range 79-380 min utes). The mean estimated blood loss was 133.1 ml (range 20-900 ml) for all procedures in this cohort. Significant suprasellar tumor extension required an extended transsphenoidal approach in 5 patients (5.8%). Labeling of CSF by intrathecal fluorescein revealed intraoperative CSF leaks in 47% of procedures. As expected, adenomas with intraoperative CSF leaks had a significantly larger diameter compared with the remaining adenomas (1.9 cm vs 1.2 cm, p < 0.01). The skull base defect was closed in a multilayered fashion with vomer (28%), Porex (4%), fat (57%), fascia lata (4%), and DuraSeal (83%). A nasoseptal flap was used in 7 patients, the majority of whom had intraoperative CSF leaks. Moreover, tumors that required nasoseptal flaps had a significantly larger diameter than tumors in which no flap was used (2.5 cm vs 1.4 cm, p < 0.05). Postoperative imaging revealed a GTR in 75.6% of all patients in our cohort ( Table 2 ). The rate of GTR was 90.6% for microadenomas and 66.7% for macroad enomas. Once functional adenomas had invaded the CS, the rate of GTR decreased to 33.3%. Thus, invasion of the CS was a significant negative predictor for GTR (OR 0.076, p < 0.001; 95% CI 0.023-0.255), whereas tumor diameter and suprasellar extension were not predictors of extent of resection. The average hospital stay was 4.3 days (range 2-32 days). The average length of the followup period from resection to laboratory testing was 22.8 months (range 1-76 months; Table 2 ).
Prolactinomas. In the current series, 35 patients with PRL-secreting adenomas underwent an endoscopic transsphenoidal tumor resection ( Table 1 ). The mean age of this group was 36.3 years (range 12-73 years), and it was composed of 22 female and 13 male patients. Those with prolactinomas were significantly younger compared with patients with GH-or ACTH-secreting adenomas (p < 0.001). The majority (80%) of these patients had at tempted medical therapy to control excess PRL secretion. Medical therapy failed for 3 main reasons: 1) insufficient control of excess hormone secretion (12 patients); 2) en largement of the pituitary adenoma despite maximum medical therapy (5 patients); and 3) intolerable adverse medication effects (11 patients). Seven patients with PRLsecreting adenomas underwent resection without a trial of medical therapy. Five of these patients presented with acute vision loss, and 2 presented with severe headaches, of which apoplexy was the cause in 5 patients. All adeno mas complicated by apoplexy were prolactinomas. Anal ysis of preoperative imaging revealed an average maxi mum diameter of 1.5 cm (range 0.4-4 cm). Thus, 62.9% of prolactinomas were classified as macroadenomas. En doscopic endonasal transsphenoidal surgery resulted in a GTR in 74.3% of patients with PRL-secreting adenomas (Table 2) . Similarly, 70.6% of patients with prolactinomas achieved endocrinological remission. Of the 24 cured pa tients, 1 required additional GKS. Resection led to a sig nificant reduction of immediate postoperative (p < 0.05) and last follow-up (p < 0.001; Table 3 ) serum PRL levels compared with preoperative levels. Of 29 patients with prolactinomas who had an intact pituitary-hypothalamic Cushing Disease. Our cohort included 18 patients in whom Cushing disease was diagnosed based on endocri nological and clinical evaluation (Table 1) . Patients with Cushing disease were on average 53.8 years old (range 25-82 years). There were 13 female and 5 male patients. The gross majority of patients (72.2%) with ACTH-pro ducing adenomas presented with classic cushingoid symp toms. Two patients received the diagnosis of Cushing disease during the workup for intractable hypertension, and 1 patient during the workup for diplopia. Analysis of preoperative imaging revealed an average maximum tumor diameter of 0.8 cm (range 0-2.3 cm). The ACTHsecreting adenomas were significantly smaller compared with both PRL-(p < 0.05) and GH-secreting (p < 0.01) adenomas. Thus, only 38.9% of ACTH-secreting adeno mas were classified as macroadenomas. No distinguish able pituitary pathological features could be identified on preoperative MR imaging in 4 patients. These patients underwent exploration of the pituitary gland without fur ther prior workup, and endocrinological remission was achieved in 2 of these 4 patients. Two patients did not achieve biochemical remission according to our criteria. One of them has ACTH and serum cortisol levels that remain consistently within normal limits 33 months after the procedure, whereas the other patient had good relief of his symptoms for 6 years, but eventually suffered from a recurrence requiring repeat resection, resulting again in alleviation of his excess cortisol production. Endoscopic endonasal transsphenoidal surgery resulted in GTR in 72.2% of patients with Cushing disease (Table 2) . How ever, only 61.1% of patients achieved endocrinological cure. Biochemical remission rates were 50% in patients with lesions that were not visible on preoperative imag ing, 54.5% in all microadenomas, and 71.4% in macroad enomas. Of 11 patients with ACTH-secreting adenomas that were cured, 2 underwent GKS. Endoscopic endona sal transsphenoidal resection led to a significant reduction of postoperative ACTH levels in serum compared with preoperative serum levels (p < 0.05; Table 3 ). Of 16 pa tients with Cushing disease who had an intact pituitaryhypothalamic axis preoperatively, 4 developed defects in one axis.
Growth Hormone-Producing Adenomas.
A total of 33 patients suffered from excess GH secretion (Table 1) . This cohort consisted of 14 female and 19 male patients, and the average age was 49.9 years (range 20-77 years). Two-thirds of patients with GH-producing adenomas presented with classic acromegalic symptoms. Four GH-secreting adeno mas were diagnosed incidentally, 2 patients sought medical attention for headaches, and 1 patient each sought help for complaints of bone pain, joint pain, diplopia, amenorrhea, or sleep apnea. Evaluation of GH-secreting adenomas on preoperative MR imaging revealed an average maximum diameter of 1.7 cm (range 0.6-4 cm). Thus, 75.8% of pa tients with acromegaly had macroadenomas, and 30.3% of GH-secreting adenomas had invaded the CS. A GTR was achieved in 78.8% of patients, and 48.5% fulfilled crite ria for endocrinological cure (Table 2) . Biochemical cure was achieved in 75% of GH-secreting microadenomas, whereas the rate was lower in macroadenomas (40%) due to a high proportion of tumors with invasion of the CS. Of 17 patients who achieved endocrinological remission, 2 underwent GKS. Endoscopic endonasal transsphenoidal resection led to a significant reduction of GH levels in se rum immediately postoperatively (p < 0.01) as well as at last follow-up (p < 0.05) compared with preoperative levels (Table 3) . A significant reduction of serum levels of IGF-I was also observed postoperatively (p < 0.001) as well as at the last follow-up (p < 0.001) compared with preoperative serum levels. Of 32 patients with GH-secreting adenomas who had an intact pituitary-hypothalamic axis preopera tively, 2 suffered from panhypopituitarism and 2 from hy pogonadism following endoscopic endonasal transsphenoi dal resection.
Predictors for Endocrinological Remission
Adenomas allowing for endocrinological remission had a significantly smaller diameter compared with le sions that were not cured (1.2 cm vs 1.8 cm, respectively; p < 0.05; Fig. 1 ). Accordingly, univariate logistic regres sion identified GTR, a maximum adenoma diameter of < 1 cm, lack of suprasellar extension, and lack of CS in vasion as positive predictors for endocrinological cure (Table 4) . When combining these significant predictors in a multivariate analysis, only GTR and suprasellar tumor extension remained significant independent predictors for biochemical remission.
Postoperative Complications
There was no operative or perioperative death in this cohort. There was 1 case of meningitis leading to hydro cephalus requiring a shunt (Table 5) . Two patients devel oped postoperative CSF leaks, which were treated with 4 days of CSF diversion via lumbar drainage. Two patients developed sinusitis after the surgery. One patient com plained of a unilateral dry eye requiring treatment with artificial tears.
Discussion
In this series of patients, we present endocrinological outcome according to the most recent updated criteria for endocrinological cure following a purely endoscopic en donasal transsphenoidal surgery for functional pituitary adenomas. The criteria for endocrinological cure have evolved over the last decades, and until now there has been little universal consensus. The use of different cri teria makes comparisons of endocrinological outcomes between different surgical series difficult. For the current series we used the latest consensus criteria for diagno sis of postoperative endocrinological remission for acro megaly, Cushing disease, and prolactinomas. 3, 9, 16 Because the endoscopic technique constitutes the latest refinement of transsphenoidal surgery, 40 a comparison of our results with a standard microscopic transsphenoidal technique was performed.
In our series endocrinological cure was achieved for 70.6% of PRL-secreting adenomas. This is similar to the weighted average cure rate (62%) derived from several mi croscopic series. 29, 33, 39, 43 It is obvious that the value of this comparison is limited due to heterogeneities of adenoma size and invasiveness, follow-up times, and definition of endocrinological cure. However, it further corroborates previous claims of equal efficiency of endoscopic tech nique for achieving biochemical cure in PRL-secreting adenomas. 12, 14 In a study of endoscopic transsphenoidal surgery by Dehdashti and colleagues, 12 the same criteria for endocrinological cure for PRL-secreting adenomas were used as in the current series (Table 6 ). However, adenoma characteristics are quite different. In the cur rent series, 8.6% of PRL-secreting adenomas required an extended approach for appropriate access to suprasellar portions, whereas adenomas that required extended ap proaches were excluded by Dehdashti et al. Moreover, the rate of CS invasion was higher in the current series (14.3%) compared with the aforementioned study (8%). This may explain the slightly higher biochemical cure rate (88%) reported by Dehdashti and colleagues for their 25 prolactinomas. The second published series reporting endocrinological outcome following endoscopic trans sphenoidal adenoma resection has a patient cohort that appears to be more similar to ours.
14 Despite endocrino logical criteria that were not as stringent as in our series (maximum serum PRL level for female patients was 30 ng/ml, compared with 20 ng/ml in the current series), the cure rate for Frank and colleagues 14 (75.7%) is similar to the rate achieved in our series. Endoscopic transsphenoi dal resection yielded endocrinological cure rates above 85% for PRL-secreting microadenomas in both stud ies 12, 14 as well as in the current series. Endocrinological remission rates for PRL-secreting adenomas with inva sion of CS differ among the series. Whereas Frank and colleagues report a cure rate (36.5%) that is comparable to the current series (60.0%), Dehdashti and colleagues do not report cures in patients with this type of lesion.
For ACTH-secreting adenomas an average cure rate of 78% is reported in the major microscopic series. 4, 7, 17, 21, 41, 46 In our series endocrinological remission was achieved in 61.1% of patients. A low rate of cure (50%) was detected in adenomas that were obscure on preoperative imaging. Moreover, endocrinological cure was achieved in only 40% of patients with visible adenomas of < 5-mm diam eter on preoperative MR imaging, whereas endocrino logical cure was obtained in 100% of microadenomas > 5 mm. Poor preoperative visualization of ACTH-secreting adenomas is a welldocumented poor prognostic factor for endocrinological remission. 6 Accordingly, we detect ed lower cure rates in ACTH-secreting microadenomas compared with those reported in studies by Frank et al. 14 and Dehdashti et al. 12 (54.5%, 67.7%, and 100%, respec tively), whereas the cure rates for macroadenomas were comparable (71.4%, 62.5%, and 68%, respectively).
The current literature on microscopic transsphe noidal resection of GH-secreting adenomas suggests an average cure rate of approximately 67%. 1, 15, 23, 31, 44, 45 In the current study endocrinological remission was achieved in only 51.5% of GH-secreting adenomas. The rate of bio chemical cure for GH-secreting microadenomas was 75% in the current series, and thus was similar to the rates reported by Frank and colleagues 14 (83%) as well as by Dehdashti and colleagues 12 (83%). Given the large pro portion of GH-secreting macroadenomas that had invad ed the CS, it is not surprising that we detected lower cure rates in GH-secreting macroadenomas compared with studies by Frank et al. and Dehdashti et al. (40%, 64 .5%, and 70.1%, respectively).
The current patient cohort includes a great propor tion of adenomas with invasion of the CS (20.9%). Using a microsurgical transsphenoidal approach, Kitano and col leagues 22 report a 67% rate of endocrinological remission in 12 patients with GH-secreting pituitary adenomas in vading the CS. Kitano and colleagues used a microscopic endoscope-assisted transsphenoidal technique to reach tu mors that had invaded the CS. The mean blood loss was approximately 1000 ml, compared with approximately 132 ml for tumors with CS invasion in our current cohort. Ki tano and colleagues report a 26% rate of transient extra ocular palsy, whereas this complication did not occur in the current series. The aggressiveness used to achieve resec tion of intracavernous tumor varies in the endoscopic lit erature. Whereas in one recent endoscopic series the inves tigators did not attempt resection of tumor from the CS, 12 Frank and Pasquini 13 report endocrinological remission in 43% of functional tumors with invasion of the CS resected using the endoscopic technique. A similar rate of cure was achieved in the current series (38.9%). It is our opinion that one must balance risk with benefit when operating in the CS, and it may be preferable to control residual tumor with stereotactic radiosurgery rather than to achieve GTR as sociated with a risk morbidity.
A potential limitation of the current study is the rela tively short followup time of 22.8 months. The occur rence of late recurrences following resection of function ing adenomas in patients with assumed endocrinological cure is well established. 2, 17, 42, 46 These recurrences have been the main motivation to introduce more and more stringent criteria for endocrinological cure. Early results from recent endoscopic series 12, 14 as well as the current study, in which no recurrences were observed in patients who achieved endocrinological remission, are encourag ing. However, continued monitoring of these patient co horts is required to eventually provide long-term endocri nological remission rates following endoscopic resection of functional pituitary adenomas.
Conclusions
An endoscopic transsphenoidal resection of function al pituitary adenomas leads to endocrinological remission in 60% of patients. Importantly, our treatment regimen of endoscopic resection in combination with GKS for pos sible residual disease allows for endocrinological remis sion in a significant proportion of functional adenomas with CS invasion as well as in recurrent adenomas, while minimizing procedure-related morbidity. 
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